Latest Administration News

OncoSil Medical has reported record dose sales and cash receipts in the first half of FY26, supported by encouraging clinical trial results and expanded European market penetration.

PlaySide Studios reported a sharp 28% revenue decline for H1 FY26 but posted a remarkable 249% jump in profit, buoyed by cost cuts and a $7.8 million tax rebate. The company also secured a $6 million loan and inked a new global publishing deal.

Sequoia Financial Group reported a 75.9% jump in operating profit for 1H FY26 despite a net loss after non-operating charges, prompting a cautious dividend cut amid regulatory challenges.

APC Minerals has announced the departure of CEO Matthew Shackleton, who led the company through challenging times including the stalled Lake Wells Sulphate of Potash Project and recent voluntary administration.

The Australian Wealth Advisors Group (AWAG) reported a 46% rise in net profit before tax for the half-year ending December 2025, driven by strong growth in funds under management and strategic joint ventures.

ADX Energy has reported encouraging flow test results from its Welchau-1 well in Austria, confirming the presence of light oil and gas condensate in the Reifling Formation. The company plans further testing to unlock the reservoir’s full potential.

Neurotech International has reported positive long-term safety results for its lead drug candidate NTI164, bolstering its path towards regulatory approval and chronic use in paediatric neurological disorders.

A recent expert panel convened by Novitas has strongly endorsed Pacific Edge’s urine-based Cxbladder tests for hematuria evaluation, recommending Medicare coverage based on robust clinical evidence and patient care benefits.

Praemium Limited reported a robust half-year performance with a 69.5% jump in net profit and a 9.6% rise in funds under administration, completing the OneVue platform transition and acquiring AI specialist Technotia Laboratories.

Alfabs Australia reported a 28% revenue rise to $55.6 million in H1 2026, but EBITDA fell due to a $2.8 million Dartbrook mine impact and softer engineering margins. The company is investing heavily in mining hire assets and pursuing a strategic acquisition to drive future growth.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Guzman y Gomez has reported a robust first half of FY26, delivering strong revenue and profit growth alongside significant restaurant network expansion in Australia and the US.